Clinical Trial

Personalized Antisense Oligonucleotide Therapy for a Participant With TARDBP ALS

Name: Personalized Antisense Oligonucleotide Therapy for a Participant With TARDBP ALS — clinical trial record (NCT07703462)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Enrolling by Invitation Phase 1/2

View on ClinicalTrials.gov →

Summary

This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for a single participant with amyotrophic lateral sclerosis (ALS) due to a pathogenic variant in TARDBP.

Trial Details

NCT Number	NCT07703462
Lead Sponsor	n-Lorem Foundation Collaborators: Thomas Jefferson University
Conditions	Amyotrophic Lateral Sclerosis (ALS)
Enrollment	1 participants
Start Date	2026-12
Primary Completion	2028-12 (estimated)
Study Completion	2028-12 (estimated)
Updated on ClinicalTrials.gov	2026-07-14